When was BostonGene founded?

BostonGene was founded in 2015 and became a unicorn in 2022, reaching the milestone in 7 years. It raised its 1st funding round 4 years after its incorporation.

Where is BostonGene located?

BostonGene is headquartered in Waltham, United States.

How many employees does BostonGene have?

As of May 31, 2026, the latest employee count at BostonGene is 373.

Is BostonGene a funded company?

BostonGene is a funded company, having raised a total of $200M across 2 funding rounds to date. The company's 1st funding round was a $50M Series A round, raised on Apr 24, 2019.

How much is BostonGene worth?

The latest valuation of BostonGene is $1B as of Apr 06, 2022.

When was the latest funding round of BostonGene?

BostonGene's latest funding was a $150M Series B round on Apr 06, 2022, with participation from 3 investors.

Is BostonGene a Healthcare IT company?

The primary sectors of BostonGene are Healthcare IT and Genomics.

Where does BostonGene rank among its competitors?

BostonGene ranks 11th amongst 420 active competitors, of which 82 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was VieCure, which secured $43M in Jan, 2026.

Who are the top competitors of BostonGene?

BostonGene's top competitors include Benchling, Helix and VieCure. Among them, VieCure secured the most recent funding round in January, 2026.

BostonGene - 2026 Company Profile, Funding & Competitors

BostonGene is a series B company based in Waltham (United States), founded in 2015. It operates as a Developer of cloud-based information and analytics platform to treat cancer. BostonGene has raised $200M in funding from NEC, with a current valuation of $1B. The company has 420 active competitors, including 82 funded and 39 that have exited. Its top competitors include companies like Benchling, Helix and VieCure.

Sectors and market segments that BostonGene operate in

BostonGene serves in the HealthTech, Life Sciences market segments.The primary business model of BostonGene are:

Company Details

Developer of cloud-based information and analytics platform to treat cancer. The company combines modern technologies, algorithms, and AI to analyze the molecular profiles of patient tumors and deliver all relevant data directly to medical professionals. The platform (MF Portrait) provides an integrated analysis of each patient's tumor microenvironment, tumor genetic profile, and clinical information.

Website: bostongene.com
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Waltham, United States

Stage

Series B

Total Funding

$200M in 2 rounds

Latest Funding Round

Series B, Apr 06, 2022, $150M

Post Money Valuation

$1B as on Apr 06, 2022

Investors

NEC & 2 more

Ranked

11^th among 420 active competitors

Employee Count

373 as on May 31, 2026

Similar Companies

Benchling & 587 more

View BostonGene's full profile

BostonGene is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BOSTONGENE CIN: 473985440 , United States, Active	Dec 31, 1999	-	83 (As on Dec 31, 2024)	-
BOSTONGENE CORPORATION CIN: 47-3985440 , United States, Active	Apr 30, 2015	-	46 (As on Dec 31, 2021)	-

BostonGene has raised a total funding of $200M over 2 rounds. Its first funding round was on Apr 24, 2019. Its latest funding round was a Series B round on Apr 06, 2022 for $150M. 3 investors participated in its latest round. BostonGene has 3 institutional investors.

Here is the list of recent funding rounds of BostonGene:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 06, 2022	$150M	Series B	$1B	-	NEC	Impact Investment Exchange, Japan Industrial Partners
Apr 24, 2019	$50M	Series A	-	-	NEC	-

Access funding benchmarks and valuations. Sign up today!

View details of BostonGene's funding rounds and investors

BostonGene's employee count trend

BostonGene has 373 employees as of May 26. Here is BostonGene's employee count trend over the years:

Uncover BostonGene's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BostonGene include Benchling, Helix and VieCure. Here is the list of Top 10 competitors of BostonGene, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Benchling 2012, San Francisco (United States), Series F	Provider of a cloud-based bioinformatics platform for biotech research	$412M	Altimeter Capital, Sequoia Capital & 28 others	73/100
2nd	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
3rd	VieCure 2015, Greenwood Village (United States), Series C	AI-based platform for generating oncology treatment plans	$113M	Northpond Ventures, Durable Capital Partners ... & 2 others	63/100
4th	Congenica 2013, Cambridge (United Kingdom), Acquired	Developer of software for clinical genomic interpretation and variant analysis	$81.9M	Puhua Capital, IDO Investments & 39 others	62/100
5th	NTxBio 2016, Santa Fe (United States), Series B	Provider of bio informatics platform to develops biologics and therapeutics	$85.1M	RA Capital Management, Anzu Partners & 5 others	61/100
6th	Latch 2021, San Francisco (United States), Series A	Provider of a web-based platform for genomic bioinformatics	$33M	Lux Capital, Coatue & 7 others	59/100
7th	Inpharmatica 1998, London (United Kingdom), Acquired	Developer of predictive informatics based platform for drug discovery	$75M	Vertex Ventures, Advent Life Sciences & 6 others	58/100
8th	SeqOne 2017, Montpellier (France), Series A	Provider of bioinformatics tools for the analysis of genome sequencing data	$48.8M	Omnes Capital, Elaia & 7 others	58/100
9th	Immuneering Corporation 2019, Cambridge (United States), Public	Provider of an AI-enabled bioinformatics platform for clinical solutions	$79M	BlackRock, Sanofi & 5 others	57/100
10th	Recludix Pharma 2020, San Diego (United States), Series A	Provider of the online platform for drug discovery and development	$60M	Access Industries, Westlake Village Biopartners ... & 1 others	57/100
11th	BostonGene 2015, Waltham (United States), Series B	Developer of cloud-based information and analytics platform to treat cancer	$200M	NEC, Japan Industrial Partners & 1 others	57/100